SAMARIUM SM-153 is a β- and γ-emitter with a physical half-life around 46.8 hours. Sm-153 treatment is recommended for patients with multiple bone metastases with the osteoblastic component, regardless of the primary tumor’s location. This compound was used in prostate cancer. It was shown that the small influence of Sm-153 on hematological parameters in patients treated with Sm-153, because of the high affinity of Sm-153 to osteoblastic metastases, and of the effect of low concentration of radionuclide in healthy bone tissue.